Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.

Younger E, Ballman K, Lu Y, Pápai Z, Van Tine BA, Attia S, Schöffski P, Reinke D, Tap WD, Jones RL.

J Geriatr Oncol. 2019 May 21. pii: S1879-4068(18)30464-8. doi: 10.1016/j.jgo.2019.05.008. [Epub ahead of print]

2.

Establishing a Mutually Respectful Environment in the Workplace: A Toolbox for Performance Excellence.

Duma N, Maingi S, Tap WD, Weekes CD, Thomas CR Jr.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e219-e226. doi: 10.1200/EDBK_249529. Epub 2019 May 17.

PMID:
31099664
3.

Multidisciplinary care in tenosynovial giant cell tumours.

Tap WD.

Lancet Oncol. 2019 Jun;20(6):755-756. doi: 10.1016/S1470-2045(19)30173-1. Epub 2019 Apr 24. No abstract available.

PMID:
31029510
4.

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.

Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD, Pandya SS, Manyak E, Jiang L, Liu G, Nimkar T, Gliser C, Prahl Judge M, Agresta S, Yang H, Dai D.

Invest New Drugs. 2019 Apr 26. doi: 10.1007/s10637-019-00771-x. [Epub ahead of print]

PMID:
31028664
5.

Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre and Post-imatinib Eras.

Cavnar MJ, Seier K, Curtin C, Balachandran VP, Coit DG, Yoon SS, Crago AM, Strong VE, Tap WD, Gönen M, Antonescu CR, Brennan MF, Singer S, DeMatteo RP.

Ann Surg. 2019 Apr 2. doi: 10.1097/SLA.0000000000003277. [Epub ahead of print]

PMID:
30946076
6.

Prognostication and Communication in Oncology.

LeBlanc TW, Marron JM, Ganai S, McGinnis MM, Spence RA, Tenner L, Tap WD, Hlubocky FJ.

J Oncol Pract. 2019 Apr;15(4):208-215. doi: 10.1200/JOP.18.00647. Epub 2019 Mar 25. No abstract available.

PMID:
30908141
7.

The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS).

Gelhorn HL, Ye X, Speck RM, Tong S, Healey JH, Bukata SV, Lackman RD, Murray L, Maclaine G, Lenderking WR, Hsu HH, Lin PS, Tap WD.

J Patient Rep Outcomes. 2019 Feb 4;3(1):6. doi: 10.1186/s41687-019-0099-0.

8.

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.

PMID:
30702028
9.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
10.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

PMID:
30575484
11.

Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.

Jones RL, Mo G, Baldwin JR, Peterson PM, Ilaria RL Jr, Conti I, Cronier DM, Tap WD.

Cancer Chemother Pharmacol. 2019 Jan;83(1):191-199. doi: 10.1007/s00280-018-3723-4. Epub 2018 Nov 8.

12.

TOMAS: revisiting PARP inhibitor combination therapy.

Nacev BA, Tap WD.

Lancet Oncol. 2018 Oct;19(10):1269-1270. doi: 10.1016/S1470-2045(18)30494-7. Epub 2018 Sep 11. No abstract available.

PMID:
30217674
13.

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD.

Oncologist. 2018 Aug 20. pii: theoncologist.2018-0160. doi: 10.1634/theoncologist.2018-0160. [Epub ahead of print]

PMID:
30126857
14.

A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.

Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, Chi P, Tap WD.

Invest New Drugs. 2019 Apr;37(2):282-290. doi: 10.1007/s10637-018-0648-z. Epub 2018 Aug 13.

PMID:
30101387
15.

Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

Murray KS, Spaliviero M, Tonorezos ES, Lacouture ME, Tap WD, Oeffinger KC, Vargas HA, Eastham JA.

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.

PMID:
29935265
16.

Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas.

Chang KK, Yoon C, Yi BC, Tap WD, Simon MC, Yoon SS.

Oncogenesis. 2018 Jun 19;7(6):47. doi: 10.1038/s41389-018-0059-1.

17.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL.

Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.

PMID:
29891538
18.

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.

Klein ME, Dickson MA, Antonescu C, Qin LX, Dooley SJ, Barlas A, Manova K, Schwartz GK, Crago AM, Singer S, Koff A, Tap WD.

Oncogene. 2018 Sep;37(37):5066-5078. doi: 10.1038/s41388-018-0332-y. Epub 2018 May 23.

19.

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

Gounder MM, Solit DB, Tap WD.

N Engl J Med. 2018 May 17;378(20):1945-1947. doi: 10.1056/NEJMc1511490. No abstract available.

20.

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2018 May;16(5):536-563. doi: 10.6004/jnccn.2018.0025.

PMID:
29752328
21.

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A.

Cancer Cell. 2018 Jul 9;34(1):9-20. doi: 10.1016/j.ccell.2018.03.023. Epub 2018 May 3. Review.

PMID:
29731395
22.

A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor.

Saltsman JA 3rd, Price AP, Goldman DA, Hammond WJ, Danzer E, Magnan H, Slotkin E, Tap WD, Heaton TE, Modak S, LaQuaglia MP.

J Pediatr Surg. 2018 Mar 6. pii: S0022-3468(18)30153-2. doi: 10.1016/j.jpedsurg.2018.02.068. [Epub ahead of print]

PMID:
29605262
23.

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.

Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055.

PMID:
29553955
24.

Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.

Kovatcheva M, Klein ME, Tap WD, Koff A.

Mol Cell Oncol. 2017 Nov 7;5(1):e1384882. doi: 10.1080/23723556.2017.1384882. eCollection 2018.

25.

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H.

Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19.

26.

Locally Aggressive Connective Tissue Tumors.

Gounder MM, Thomas DM, Tap WD.

J Clin Oncol. 2018 Jan 10;36(2):202-209. doi: 10.1200/JCO.2017.75.8482. Epub 2017 Dec 8.

PMID:
29220303
27.

Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?

Chudgar NP, Brennan MF, Tan KS, Munhoz RR, D'Angelo SP, Bains MS, Huang J, Park BJ, Adusumilli PS, Tap WD, Jones DR.

Ann Thorac Surg. 2017 Dec;104(6):1837-1845. doi: 10.1016/j.athoracsur.2017.07.024. Epub 2017 Nov 2.

28.

Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.

Cavnar MJ, Wang L, Balachandran VP, Antonescu CR, Tap WD, Keohan M, Singer S, Temple L, Nash GM, Weiser MR, Guillem JG, Aguilar JG, DeMatteo RP, Paty PB.

Ann Surg Oncol. 2017 Dec;24(13):3972-3980. doi: 10.1245/s10434-017-6087-9. Epub 2017 Oct 20.

29.

GeDDiS: insight into frontline therapy in soft tissue sarcoma.

Tap WD.

Lancet Oncol. 2017 Oct;18(10):1297-1299. doi: 10.1016/S1470-2045(17)30672-1. Epub 2017 Sep 4. No abstract available.

30.

ATRX is a regulator of therapy induced senescence in human cells.

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A.

Nat Commun. 2017 Aug 30;8(1):386. doi: 10.1038/s41467-017-00540-5.

31.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P.

Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Erratum in: Lancet Oncol. 2018 Feb;19(2):e78.

PMID:
28651927
32.

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.

Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D'Angelo SP, Bains MS, Bott M, Huang J, Park BJ, Rusch VW, Adusumilli PS, Tap WD, Singer S, Jones DR.

J Thorac Cardiovasc Surg. 2017 Jul;154(1):319-330.e1. doi: 10.1016/j.jtcvs.2017.02.061. Epub 2017 Mar 21.

33.

Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma.

Di Gialleonardo V, Aldeborgh HN, Miloushev V, Folkers KM, Granlund K, Tap WD, Lewis JS, Weber WA, Keshari KR.

Cancer Res. 2017 Jun 1;77(11):3113-3120. doi: 10.1158/0008-5472.CAN-16-3310. Epub 2017 Apr 6.

34.

Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation.

van Hell AJ, Haimovitz-Friedman A, Fuks Z, Tap WD, Kolesnick R.

Cell Signal. 2017 Jun;34:86-91. doi: 10.1016/j.cellsig.2017.02.021. Epub 2017 Feb 24.

35.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

36.

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD.

Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22.

37.

BCOR upregulation in a poorly differentiated synovial sarcoma with SS18L1-SSX1 fusion-A pathologic and molecular pitfall.

Kao YC, Sung YS, Zhang L, Kenan S, Singer S, Tap WD, Swanson D, Dickson BC, Antonescu CR.

Genes Chromosomes Cancer. 2017 Apr;56(4):296-302. doi: 10.1002/gcc.22435. Epub 2017 Jan 4.

38.

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK.

Ann Oncol. 2016 Oct;27(10):1855-60. doi: 10.1093/annonc/mdw281. Epub 2016 Aug 8.

39.

Current status of engineered T-cell therapy for synovial sarcoma.

Dallos M, Tap WD, D'Angelo SP.

Immunotherapy. 2016 Sep;8(9):1073-80. doi: 10.2217/imt-2016-0026. Review.

40.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR.

J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. Erratum in: J Clin Oncol. 2017 Mar;35(7):812.

41.

Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.

Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS.

Oncotarget. 2016 Jul 12;7(28):42844-42858. doi: 10.18632/oncotarget.10212.

42.

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.

Shoushtari AN, Landa J, Kuk D, Sanchez A, Lala B, Schmidt N, Okoli C, Chi P, Dickson MA, Gounder MM, Keohan ML, Crago AM, Tap WD, D'Angelo SP.

Sarcoma. 2016;2016:3547497. doi: 10.1155/2016/3547497. Epub 2016 May 29.

43.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK.

Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464.

44.

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J.

J Natl Compr Canc Netw. 2016 Jun;14(6):758-86.

PMID:
27283169
45.

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Dickson MA, Schwartz GK, Keohan ML, D'Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, Tap WD.

JAMA Oncol. 2016 Jul 1;2(7):937-40. doi: 10.1001/jamaoncol.2016.0264.

46.

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.

Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, Lenderking W, Ye X, Speck RM, Lackman RD, Bukata SV, Healey JH, Keedy VL, Anthony SP, Wagner AJ, Von Hoff DD, Singh AS, Becerra CR, Hsu HH, Lin PS, Tap WD.

Clin Ther. 2016 Apr;38(4):778-93. doi: 10.1016/j.clinthera.2016.03.008. Epub 2016 Apr 1.

47.

Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.

Huang SC, Zhang L, Sung YS, Chen CL, Kao YC, Agaram NP, Singer S, Tap WD, D'Angelo S, Antonescu CR.

Am J Surg Pathol. 2016 May;40(5):645-55. doi: 10.1097/PAS.0000000000000582.

48.

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.

Munhoz RR, D'Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, Qin LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA.

Oncologist. 2015 Nov;20(11):1245-6. doi: 10.1634/theoncologist.2015-0245. Epub 2015 Oct 8.

49.

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.

Anderson JL, Park A, Akiyama R, Tap WD, Denny CT, Federman N.

PLoS One. 2015 Sep 24;10(9):e0133610. doi: 10.1371/journal.pone.0133610. eCollection 2015.

50.

Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases.

Spratt DE, Arevalo-Perez J, Leeman JE, Gerber NK, Folkert M, Taunk NK, Alektiar KM, Karimi S, Lyo JK, Tap WD, Bilsky MH, Laufer I, Yamada Y, Osborne JR.

Spine J. 2016 Mar;16(3):291-8. doi: 10.1016/j.spinee.2015.08.041.

Supplemental Content

Support Center